Novel Androgen Deprivation Treatment for Advanced Prostate Cancer
By Annenberg Center for Health Sciences
Prostate cancer is the most common cancer diagnosed among men in the United States. Considered curable if diagnosed at a localized stage, the survival rate of men with metastatic disease is dramatically reduced. Due to the androgen-dependence of prostate cancer, androgen deprivation therapy (ADT) has been the mainstay and primary therapeutic approach for management of men with metastatic prostate cancer. Join Drs. Robert Dreicer and Michael Cookson as they review the principles of androgen deprivation therapy and discuss the latest clinical data for recently approved ADT agents and studies of
Novel Androgen Deprivation Treatment for Advanced Prostate CancerDec 10, 2021
00:00
07:57
Patient Preferences
Patient Preferences
Dec 10, 202107:57
Exploring Optimal Therapeutic Options
Exploring Optimal Therapeutic Options
Dec 10, 202119:16
Current State of Care in Advanced PCa
Current State of Care in Advanced PCa
Dec 10, 202140:03
Androgen Deprivation Therapy: Clinical Differences
Androgen Deprivation Therapy: Clinical Differences
Dec 10, 202110:11